Clinical Roundup Similar results reported in comparison of pirtobrutinib vs. ibrutinib to treat CLL, SLL, OSU study finds December 19, 2025Vol.51 No.46
Clinical Roundup Retifanlimab-dlwr demonstrates 11-month OS difference for anal cancer patients in phase III trial December 19, 2025Vol.51 No.46
Clinical Roundup Cedars-Sinai researchers develop risk score to help predict pancreatic cancer recurrence December 19, 2025Vol.51 No.46
Clinical Roundup Drug combination kills OVCAR3 ovarian cancer cells, UNM researchers find December 19, 2025Vol.51 No.46
Clinical Roundup Blood test detects lung cancer up to 5 years before scans, Personalis and University College London study finds December 19, 2025Vol.51 No.46
Drugs & Targets FDA grants regular approval to rucaparib for metastatic castration-resistant prostate cancer December 19, 2025Vol.51 No.46
Drugs & Targets FDA and OS Therapies hold Type C meeting regarding phase IIb clinical trial of OST-HER2 in the prevention or delay of recurrent, fully resected, pulmonary metastatic osteosarcoma December 19, 2025Vol.51 No.46
Drugs & Targets FDA awards National Priority Voucher to Tecvayli+Darzalex based on phase III study results December 19, 2025Vol.51 No.46
Drugs & Targets EC approval of Minjuvi in relapsed or refractory follicular lymphoma December 19, 2025Vol.51 No.46
Conversation with The Cancer Letter John Byrd brings blood cancer expertise to solid tumor, immunology powerhouse at UPMC December 12, 2025Vol.51 No.45By Jacquelyn Cobb and Paul Goldberg
